CMS Agrees With Industry: PET Coverage Process Should Be Overhauled
This article was originally published in The Gray Sheet
Executive Summary
Medical imaging equipment manufacturers should play a more active role in the development of Medicare coverage policies for diagnostic imaging technologies, CMS Coverage & Analysis Director Steve Phurrough said May 7 at an AdvaMed meeting on Medicare policy in Baltimore
You may also be interested in...
Call For More PET Tech Assessment Studies To Shape CMS Coverage Debate
Preliminary evidence bodes well for positron emission tomography (PET) to be used as an adjunct in initially diagnosing cervical, ovarian, pancreatic, small-cell lung and testicular cancers, but further confirmatory studies are needed, according to AHRQ
Call For More PET Tech Assessment Studies To Shape CMS Coverage Debate
Preliminary evidence bodes well for positron emission tomography (PET) to be used as an adjunct in initially diagnosing cervical, ovarian, pancreatic, small-cell lung and testicular cancers, but further confirmatory studies are needed, according to AHRQ
Improved Clinical Outcomes After FDG-PET Diagnosis Key To Coverage – CMS
CMS' decision to deny Medicare coverage of FDG-PET for soft tissue sarcoma and most thyroid cancer indications is consistent with the MCAC recommendation that standards of evidence should not be relaxed for diagnostics of rare diseases